Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

270.24

+2.87 (1.07%)

as of Aug 21, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Aug 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown some volatility recently, primarily due to performance issues in its cardio business, despite reporting a solid beat-and-raise quarter. The company has successfully addressed past legal challenges related to talcum powder, minimizing the overhang of these lawsuits. Analysts are optimistic about JNJ’s upcoming earnings report expected on July 15, anticipating positive news about its oncology drugs and orthopedic business, although caution persists due to erratic stock movements following disclosure of results. The spin-off of the orthopedics division is viewed positively as it shifts focus towards higher-margin pharmaceutical and medical device sectors. Overall, JNJ is seen as a solid investment due to its strong drug pipeline and improved balance sheet, even as the company navigates its litigation concerns.

Consensus

Buy

Valuation

Fair Value

Similar

BUY

This would be a fine way of playing the healthcare area. It's a defensive company. Had a few issues with the stent market, but the rest of their operations are just great.

BUY

Not only is this a pharmaceutical company, which he likes, it is also a medical device company as well as consumer products. Very well run, good company. Cheap. Good pipeline.

BUY

A lot of the US big cap stocks have good international exposure. His Fair Market Value is over $125 so there is a lot of potential. The next major resistance point is $73.50.

BUY

US pharmaceuticals are a good defensive place to be.

BUY

US$ decline is positive for this global company. Defensive. Good international diversification. Good revenue streams. Some speculation that they may be an acquirer of Colgate-Palmolive, which could put them under pressure.

BUY

Stock has done absolutely nothing for the last 5 to 7 years. Valuation is somewhere between $85 and $100. Acquisition of Pfizer’s (PFE-N) consumer products division has been adding good value to the company's earnings quality. A good anchor to a portfolio.

WAIT

A sort of a consumer related Dow component stock. These are all getting into trouble, so wait and let this run its course.

BUY ON WEAKNESS

On his watch list. Nice diversified large cap situation. Decent dividend yield. A good mix of business. Would like to buy below $60.

COMMENT

If you were long-term investor, this is a Buy. Have the premiere products. In the near term, it hasn't done very well and probably is not going anywhere, because a number of their drugs have come off patent, had some issues with drug coated stents.

BUY

Thinks the shares should be selling at $75.

BUY

Pharmaceuticals are relatively defensive plays at these prices. All impacted by generic drugs. This company has very little in the way of drug exploration and generic competition. Good consumer-products division.

TOP PICK

Isn't getting much respect. Trading at about 15 X this year's earnings and probably 13.5 X next years. With the strong Cdn$, this is a great time to get into this. Nice dividend. Returning over 20% on equity.

PAST TOP PICK

(A Top Pick July 4/06. Up 6.8%.) An interesting play on demographics. A lot of litigation on drug companies. Pays a good dividend.

BUY ON WEAKNESS

Analysts have target around the $72 area. Current PE is around 16. Earnings are coming out tomorrow, so hold off until these are released. Doesn't like to play them after they've had their first bounce.

BUY

Has under performed since its high in October. Pharmaceutical industry is facing a lot of issues. Trades around 12 X earnings with a yield of about 2.3%. Very well run company. Expecting very good earnings growth. Throws up a lot of free cash flow.

Showing 526 to 540 of 628 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Darren Sissons

Campbell Lee & Ross

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Johnson & Johnson (JNJ)